

Dear Manufacturers,

I am writing on behalf of Tucson Medical Center (TMC), 340B ID: DSH030006, to inform manufacturers that TMC recently underwent an audit by the Health Resources and Services Administration (HRSA) of TMC's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, TMC located in Tucson, AZ qualified for the 340B Program as Disproportionate Share Hospital (DSH) and has participated in the 340B Program since April 1, 2005.

Through the audit process, TMC was found to have non-compliance within their 340B Program and responsible for repayment as a result of the following findings:

Self-Disclosure: Duplicate Discounts

TMC does not have adequate controls to prevent duplicate discounts which resulted in duplicate discounts as prohibited by 42 USC 256b(a)(5)(A).

Finding 1: TMC dispensed a 340B drug to ineligible individuals from contract pharmacy locations, as prohibited by 42 USC 256b(a)(5)(B).

TMC has identified all affected manufacturers by manufacturer's Label Code and corresponding address/contact name within the HRSA/OPA Manufacturer Database, and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers have not received notification from TMC and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact Gilbert Romero, Director of Pharmacy, Tucson Medical Center, 5301 Grant Road, Tucson, AZ 85712, Office Phone - 520-324-3341.

The 340B Program is vital to TMC and we are firmly committed to meeting all compliance standards.

Sincerely,

Tim Hartin
Senior Vice President, Chief Legal Officer
Tucson Medical Center